Literature DB >> 17996649

Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.

Francesco Fazi1, Serena Racanicchi, Giuseppe Zardo, Linda M Starnes, Marco Mancini, Lorena Travaglini, Daniela Diverio, Emanuele Ammatuna, Giuseppe Cimino, Francesco Lo-Coco, Francesco Grignani, Clara Nervi.   

Abstract

Hematopoietic transcription factors are involved in chromosomal translocations, which generate fusion proteins contributing to leukemia pathogenesis. Analysis of patient's primary leukemia blasts revealed that those carrying the t(8;21) generating AML1/ETO, the most common acute myeloid leukemia-associated fusion protein, display low levels of a microRNA-223 (miR-223), a regulator of myelopoiesis. Here, we show that miR-223 is a direct transcriptional target of AML1/ETO. By recruiting chromatin remodeling enzymes at an AML1-binding site on the pre-miR-223 gene, AML1/ETO induces heterochromatic silencing of miR-223. Ectopic miR-223 expression, RNAi against AML1/ETO, or demethylating treatment enhances miR-223 levels and restores cell differentiation. Here, we identify an additional action for a leukemia fusion protein linking the epigenetic silencing of a microRNA locus to the differentiation block of leukemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17996649     DOI: 10.1016/j.ccr.2007.09.020

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  160 in total

1.  miRNAs in human cancer.

Authors:  Xiaomin Zhong; George Coukos; Lin Zhang
Journal:  Methods Mol Biol       Date:  2012

Review 2.  DNA methylation and microRNAs in cancer.

Authors:  Xiang-Quan Li; Yuan-Yuan Guo; Wei De
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  Selective upregulation of microRNA expression in peripheral blood leukocytes in IL-10-/- mice precedes expression in the colon.

Authors:  Jeremy S Schaefer; Dina Montufar-Solis; Nadarajah Vigneswaran; John R Klein
Journal:  J Immunol       Date:  2011-10-31       Impact factor: 5.422

4.  RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).

Authors:  R Katherine Hyde; P Paul Liu
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

5.  Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.

Authors:  Matteo Brioschi; John Fischer; Roberto Cairoli; Stefano Rossetti; Laura Pezzetti; Michele Nichelatti; Mauro Turrini; Francesca Corlazzoli; Barbara Scarpati; Enrica Morra; Nicoletta Sacchi; Alessandro Beghini
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

6.  AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.

Authors:  X N Gao; F Yan; J Lin; L Gao; X L Lu; S C Wei; N Shen; J X Pang; Q Y Ning; Y Komeno; A L Deng; Y H Xu; J L Shi; Y H Li; D E Zhang; C Nervi; S J Liu; L Yu
Journal:  Leukemia       Date:  2015-03-02       Impact factor: 11.528

7.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

8.  Complete characterization of the microRNAome in a patient with acute myeloid leukemia.

Authors:  Giridharan Ramsingh; Daniel C Koboldt; Maria Trissal; Katherine B Chiappinelli; Todd Wylie; Sunita Koul; Li-Wei Chang; Rakesh Nagarajan; Todd A Fehniger; Paul Goodfellow; Vincent Magrini; Richard K Wilson; Li Ding; Timothy J Ley; Elaine R Mardis; Daniel C Link
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

Review 9.  MicroRNA-mediated control of macrophages and its implications for cancer.

Authors:  Mario Leonardo Squadrito; Martin Etzrodt; Michele De Palma; Mikael J Pittet
Journal:  Trends Immunol       Date:  2013-03-13       Impact factor: 16.687

10.  microRNA Regulation and Its Consequences in Cancer.

Authors:  Sonya Parpart; Xin Wei Wang
Journal:  Curr Pathobiol Rep       Date:  2012-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.